TimesSquare Capital Management, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 368 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2024. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.

Quarter-by-quarter ownership
TimesSquare Capital Management, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2024$28,182,471
+106176.8%
411,483
+7.4%
0.44%
+14.8%
Q1 2024$26,518
-25.4%
383,211
-22.8%
0.39%
-26.2%
Q4 2023$35,549
+36.0%
496,350
-1.1%
0.52%
+28.5%
Q3 2023$26,130
-9.0%
501,625
+10.6%
0.41%
-1.2%
Q2 2023$28,708
+3.7%
453,375
-11.3%
0.41%
+2.0%
Q1 2023$27,675
-26.1%
511,075
-27.8%
0.40%
-24.2%
Q4 2022$37,467
-99.9%
708,000
-20.0%
0.53%
-7.0%
Q3 2022$41,203,000
-9.9%
885,510
+10.6%
0.57%
-10.0%
Q2 2022$45,712,000
-14.8%
800,838
-8.7%
0.64%
+5.8%
Q1 2022$53,665,000
-23.7%
877,028
-34.7%
0.60%
-3.4%
Q4 2021$70,343,000
+9.8%
1,343,965
-21.8%
0.62%
+11.4%
Q3 2021$64,072,000
+36.1%
1,718,665
+49.0%
0.56%
+45.2%
Q2 2021$47,081,000
+13.1%
1,153,380
-6.0%
0.38%
+7.8%
Q1 2021$41,642,000
+47.3%
1,227,280
+38.0%
0.36%
+55.2%
Q4 2020$28,277,000
+22.1%
889,200
-1.5%
0.23%
+6.0%
Q3 2020$23,158,000
-0.0%
902,500
-41.2%
0.22%
+40.0%
Q4 2016$23,162,000
-13.5%
1,534,938
-12.6%
0.16%
-10.4%
Q3 2016$26,770,000
-57.4%
1,756,575
+8.4%
0.17%
-58.4%
Q2 2016$62,884,000
+48.4%
1,619,875
+6.3%
0.42%
+50.2%
Q1 2016$42,378,000
-40.2%
1,524,375
+15.6%
0.28%
-38.0%
Q4 2015$70,918,000
+61.0%
1,318,420
+19.9%
0.45%
+62.0%
Q3 2015$44,044,0001,100,0000.28%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2024
NameSharesValueWeighting ↓
Sarissa Capital Management LP 360,000$11,502,0002.65%
Redmile Group, LLC 610,171$19,495,0001.60%
Pier Capital, LLC 257,256$8,219,0001.18%
WALL STREET ASSOCIATES 358,857$11,465,0001.08%
SENZAR ASSET MANAGEMENT, LLC 161,300$5,154,0000.88%
Rhenman & Partners Asset Management AB 206,000$6,582,0000.79%
EAM Investors, LLC 152,389$4,869,0000.57%
EDMOND DE ROTHSCHILD (SUISSE) S.A. 50,000$1,598,0000.51%
Visium Asset Management, LP 1,051,479$33,595,0000.48%
SPHERA FUNDS MANAGEMENT LTD. 128,000$4,090,0000.40%
View complete list of INTRA CELLULAR THERAPIES INC shareholders